Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue.
Tarsus Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Jun. 2026 was -0.59. The higher Degree of Operating Leverage, the higher operating risk the company will take.
The industry rank for Tarsus Pharmaceuticals's Degree of Operating Leverage or its related term are showing as below:
TARS's Degree of Operating Leverage is ranked better than 65.54% of 859
companies
in the Biotechnology industry
Industry Median: 0.01
vs TARS: -0.59
Tarsus Pharmaceuticals (NAS:TARS) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Tarsus Pharmaceuticals Degree of Operating Leverage Related Terms
Tarsus Pharmaceuticals Degree of Operating Leverage Historical Data
* Premium members only.
The historical data trend for Tarsus Pharmaceuticals's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals Degree of Operating Leverage Chart
TARS vs IMNM, NAMS, IRON: Degree of Operating Leverage Comparison
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals Degree of Operating Leverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Degree of Operating Leverage falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
What does a Degree of Operating Leverage of -0.59 mean?
Tarsus Pharmaceuticals (TARS) has a Degree of Operating Leverage of -0.59 as of Jun. 2026. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Tarsus Pharmaceuticals and its competitors. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #296 out of 859 companies in the Biotechnology industry, placing it in the top 34.5%.
Is Tarsus Pharmaceuticals' Degree of Operating Leverage too high?
Tarsus Pharmaceuticals' current Degree of Operating Leverage is -0.59. Based on the distribution chart, Tarsus Pharmaceuticals ranks #296 out of 859 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tarsus Pharmaceuticals has a GF Score™ of 47/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Degree of Operating Leverage compare to IMNM and NAMS?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #296 out of 859 companies for Degree of Operating Leverage. This puts Tarsus Pharmaceuticals in the upper half of its industry. The industry median Degree of Operating Leverage is 0.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Operating Leverage for a Biotechnology company?
The median Degree of Operating Leverage among Biotechnology companies is 0.01, based on 859 companies in the industry. Companies in the top quartile (top 25%) have a Degree of Operating Leverage significantly above this median, while those in the bottom quartile fall well below. However, Degree of Operating Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Operating Leverage mean?
A high Degree of Operating Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median Degree of Operating Leverage is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current Degree of Operating Leverage is -0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Significantly Undervalued. The stock's GF Value™ is $160.30, compared to a current price of $79.31 — trading 50.5% below its estimated fair value. The current Degree of Operating Leverage is -0.59. Tarsus Pharmaceuticals' overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Operating Leverage calculated?
Degree of Operating Leverage is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Degree of Operating Leverage is -0.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $79.31 is trading 50.5% below its estimated GF Value™ of $160.30.
GuruFocus considers Tarsus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for TARS:
Degree of Operating Leverage: -0.59
GF Value™: $160.30 vs. price of $79.31 (50.5% below fair value)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
47GF Score
Get the complete analysis for TARS
Degree of Operating Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
